StockData
Pulmatrix, Inc. logo

Pulmatrix, Inc. (PULM) company profile

PULMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.37+0.04 (+3.01%)

Close on Nov 17, 2026Market cap $5.00MP/E –Yield –

About Pulmatrix

Pharmaceutical Preparations, SIC 2834

Pulmatrix, Inc. is a biopharmaceutical company focused on developing inhaled therapeutic products to prevent and treat central nervous system disorders and serious respiratory diseases. Using its proprietary dry powder delivery technology platform, iSPERSE, the company designs small, dense, and dispersible particles that deliver small or large molecule drugs into the airways without reliance on conventional lactose blends. Its proprietary clinical product pipeline includes PUR3100 for acute migraine, PUR1800 for acute exacerbations of chronic obstructive pulmonary disease, and PUR1900 for allergic bronchopulmonary aspergillosis in patients with asthma or cystic fibrosis.

The company operates its corporate office in Framingham, Massachusetts. Following a strategic review, the company agreed to merge with Cullgen Inc. and has paused active clinical development across its product pipeline while exploring opportunities to license or monetize its assets and delivery platform.

Summary of the business section of Pulmatrix's latest annual report, written by StockData.

Company profile

Company

Legal name
Pulmatrix, Inc.
Founded
2013
Headquarters
Framingham, MA
Address
945 Concord Street, Suite 1217 01701
Phone
(888) 355-4440
Employees
2, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Marcum LLP, New York, NY

Stock & identifiers

Ticker
PULM
Former tickers
RTGN until Aug 14, 2015
Exchange
Nasdaq
IPO date
Mar 21, 2014
Shares outstanding
4M, Aug 13, 2026
Public float
$25.20M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Mar 1, 2022; 1-for-10 reverse, Feb 6, 2019; 1-for-2.5 reverse, Jun 16, 2015
SEC CIK
1574235
CUSIP
74584P301
ISIN
US74584P3010
FIGI
BBG003TH2QL1
Share class FIGI
BBG003TH2QM0
LEI
5299002RHCRZ9ST3GN42
EIN
46-1821392

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

No recent ownership filings by officers or directors

Pulmatrix's leadership is listed in its proxy statement, last filed Nov 8, 2024.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 21, 2014
Offer price
$7.25
Securities offered
2,650,000
Gross proceeds
$19.21M
Exchange
Nasdaq
First trading day
Mar 21, 2014
First-day close
$7.250.0%
Lock-up ends (est.)
Sep 17, 2014

“Per Unit Total Public offering price $ 7.25 $ 19,212,500 Underwriting discounts and commissions (1) $ 0.58 $ 1,537,000 Offering proceeds to us, before expenses $ 6.67 $ 17,675,500 (1) Does not include a non-accountable expense allowance equal to 1% of the gross proceeds of this offering payable to Dawson James Sec”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had two full-time employees, both of whom were engaged in full-time administrative activities.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?